Pfizer Opens Phase 3 Test of Weekly Berobenatide in Chinese Obesity Cohort
Pfizer has launched a phase 3 trial of berobenatide, the company’s once-weekly injectable therapy for adults in China with overweight or obesity. The study is designed to measure whether the drug can drive clinically meaningful weight loss while maintaining an acceptable safety profile against placebo. For a condition tied to cardiometabolic disease, diabetes, and downstream organ damage, the choice of a weekly regimen is clinically important: adherence tends to erode when treatment demands become burdensome, and a once-weekly schedule may improve persistence in real-world use.
The trial is registered as a randomized, double-blind, placebo-controlled phase 3 study with an estimated enrollment of 300 participants. Recruitment is underway across 34 locations in China, including major academic and regional hospitals in Tianjin, Beijing, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Shanghai, Hangzhou, and other cities. The broad site network signals an effort to enroll a heterogeneous adult population rather than a narrow single-center sample, which matters in obesity research because body mass index, diabetes burden, and prior treatment history can vary widely across practice settings.
Eligibility is tightly drawn. Adults must be at least 18 years old and meet one of two weight thresholds: a body mass index of 28 kg/m² or higher, or a body mass index between 24 and 28 kg/m² paired with at least one weight-related comorbidity. Participants with type 2 diabetes must have HbA1c values between 6.5% and 10.0%, and all candidates must have attempted weight loss through diet without success at least once before enrollment. Those criteria point to a population in which lifestyle intervention alone has already proven insufficient, creating a clinically relevant setting for pharmacologic therapy.
A brief exclusion list sharpens the safety boundaries. Recent significant weight change of more than 5% within three months excludes participation, as do type 1 diabetes, prior pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, recent bariatric surgery or other obesity procedures, pregnancy, and breastfeeding. The exclusions track familiar concerns in obesity drug development, especially where pancreatic and thyroid safety remain part of the risk calculus for incretin-based and related weight-loss therapies.
Why the Design Fits the Biology of Chronic Weight Management
The study uses a randomized, parallel-assignment structure with quadruple masking, covering participants, care providers, investigators, and outcomes assessors. That level of masking is not cosmetic. In obesity trials, expectations can strongly influence perceived appetite, reporting of gastrointestinal symptoms, and even dropout patterns, so blinding protects the interpretability of both efficacy and tolerability signals.
Participants are assigned to one of three arms. One experimental group receives berobenatide at a medium maintenance dose after a dose-escalation phase, another receives a low maintenance dose after escalation, and the control group receives placebo matched to the low-dose regimen. The study treatment is administered once weekly throughout dose escalation and maintenance. Because the protocol includes both low and medium maintenance dosing, it appears built to explore whether a lower exposure can preserve benefit while limiting adverse effects, a practical question in chronic metabolic disease where the balance between efficacy and tolerability often determines whether therapy is usable beyond the trial setting.
Obesity is not a cosmetic condition; it is a chronic disease with mechanistic links to insulin resistance, blood pressure elevation, dyslipidemia, fatty liver disease, and inflammatory stress. A therapy that reliably reduces body weight can improve those pathways at the source, but only if the drug can be sustained long enough for that biology to shift. Weekly dosing is attractive because it may align with the long arc of weight management better than daily regimens that require constant behavioral reinforcement.
One sentence captures the practical stakes: the trial is set up to determine whether a once-weekly injectable can move weight loss from theory into routine use.
A China-Specific Trial With Broad Relevance Beyond the Study Sites
The study population is restricted to Chinese adults, which gives the trial a distinct regional focus. Body composition, diet patterns, diabetes prevalence, and baseline BMI distributions differ across populations, and obesity thresholds used in Asian populations often reflect risk at lower BMI ranges than those applied in Western cohorts. The trial’s inclusion criteria mirror that reality by allowing participation at BMI levels starting at 24 kg/m² when weight-related comorbidity is already present.
That design choice should help answer a clinically important question: can a weekly pharmacologic strategy benefit patients who may not meet the very high BMI thresholds often seen in Western obesity studies, but who still carry substantial cardiometabolic risk? If efficacy is demonstrated, the data could be especially relevant for health systems managing large numbers of adults who fall into the overweight range yet already have diabetes or other obesity-related disease.
The estimated timeline stretches from an actual study start date of September 24, 2026, to a primary completion date of March 14, 2028, with overall completion expected by May 23, 2028. Those dates mean the trial is still in progress and no outcomes are posted yet. The absence of results leaves the main questions open: whether the drug can produce enough weight reduction to matter clinically, whether any benefit is durable across maintenance dosing, and whether tolerability holds up over a prolonged treatment course.
Safety Boundaries Will Matter as Much as the Scale Reading
Weight-loss programs fail in predictable ways when adverse effects undermine persistence. Nausea, vomiting, abdominal discomfort, and other treatment-emergent symptoms can derail adherence even when early efficacy looks impressive, so the eventual readout will need to separate transient dose-escalation effects from persistent safety problems. The exclusion of people with prior pancreatitis and those at risk for medullary thyroid carcinoma or MEN2 shows how carefully the protocol is positioned around known or suspected class concerns.
Because the study is placebo-controlled, its eventual value will depend on more than headline weight loss. Clinicians will want to see whether reductions in body weight come with acceptable discontinuation rates, whether people with type 2 diabetes tolerate the regimen differently from those without diabetes, and whether the lower and medium maintenance doses diverge enough to justify one over the other in practice.
The trial’s final readout is still ahead, and the core clinical questions remain straightforward: how much weight reduction will berobenatide deliver, which dose will be easiest to sustain, and whether safety remains compatible with long-term obesity care.